 Erin Harvey
Concepts (138)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Asthmatic Agents | 9 | 2025 | 393 | 2.350 |
Why?
| | Asthma | 15 | 2025 | 2290 | 1.870 |
Why?
| | Viruses | 7 | 2025 | 112 | 1.830 |
Why?
| | Antibodies, Monoclonal, Humanized | 7 | 2025 | 807 | 1.740 |
Why?
| | RNA Viruses | 4 | 2025 | 40 | 1.640 |
Why?
| | Australia | 19 | 2025 | 314 | 1.480 |
Why?
| | Adrenal Cortex Hormones | 5 | 2025 | 555 | 0.980 |
Why?
| | Palaemonidae | 1 | 2022 | 1 | 0.800 |
Why?
| | Carps | 1 | 2022 | 4 | 0.800 |
Why?
| | Nodaviridae | 1 | 2022 | 4 | 0.800 |
Why?
| | Ticks | 2 | 2020 | 25 | 0.770 |
Why?
| | Eosinophils | 2 | 2025 | 331 | 0.750 |
Why?
| | Phylogeny | 8 | 2025 | 898 | 0.650 |
Why?
| | Siphonaptera | 1 | 2019 | 15 | 0.640 |
Why?
| | Phascolarctidae | 1 | 2019 | 1 | 0.630 |
Why?
| | Genome, Viral | 2 | 2024 | 144 | 0.620 |
Why?
| | DNA Viruses | 1 | 2019 | 14 | 0.620 |
Why?
| | Chlamydia | 1 | 2019 | 10 | 0.620 |
Why?
| | Tick-Borne Diseases | 1 | 2019 | 10 | 0.620 |
Why?
| | Microbial Interactions | 1 | 2019 | 18 | 0.610 |
Why?
| | RNA Virus Infections | 1 | 2019 | 15 | 0.610 |
Why?
| | Lyme Disease | 1 | 2019 | 58 | 0.580 |
Why?
| | Chlamydia Infections | 1 | 2019 | 74 | 0.570 |
Why?
| | Anxiety | 1 | 2025 | 1041 | 0.570 |
Why?
| | Biodiversity | 3 | 2025 | 405 | 0.560 |
Why?
| | Coinfection | 1 | 2019 | 137 | 0.550 |
Why?
| | Registries | 8 | 2025 | 2021 | 0.530 |
Why?
| | Depression | 1 | 2025 | 1408 | 0.500 |
Why?
| | Marsupialia | 3 | 2025 | 6 | 0.440 |
Why?
| | Speech Perception | 2 | 2025 | 89 | 0.410 |
Why?
| | Cochlear Implantation | 2 | 2025 | 93 | 0.400 |
Why?
| | Severity of Illness Index | 8 | 2025 | 2838 | 0.390 |
Why?
| | Metagenomics | 3 | 2024 | 167 | 0.380 |
Why?
| | Administration, Oral | 2 | 2025 | 814 | 0.340 |
Why?
| | Virology | 2 | 2021 | 25 | 0.330 |
Why?
| | Quality of Life | 5 | 2025 | 2870 | 0.320 |
Why?
| | Animals, Wild | 2 | 2020 | 58 | 0.320 |
Why?
| | Microsurgery | 2 | 2025 | 80 | 0.270 |
Why?
| | Neuroma, Acoustic | 2 | 2025 | 52 | 0.270 |
Why?
| | Coral Reefs | 1 | 2025 | 8 | 0.240 |
Why?
| | Radiosurgery | 2 | 2025 | 346 | 0.220 |
Why?
| | Fishes | 1 | 2025 | 100 | 0.220 |
Why?
| | Cichlids | 1 | 2024 | 4 | 0.220 |
Why?
| | Remission Induction | 4 | 2025 | 287 | 0.220 |
Why?
| | Animals | 11 | 2025 | 37011 | 0.210 |
Why?
| | Treatment Outcome | 7 | 2025 | 10821 | 0.210 |
Why?
| | Pulmonary Eosinophilia | 1 | 2022 | 27 | 0.200 |
Why?
| | Larynx | 1 | 2023 | 60 | 0.200 |
Why?
| | Respiration Disorders | 1 | 2023 | 77 | 0.200 |
Why?
| | Nasal Polyps | 1 | 2022 | 59 | 0.190 |
Why?
| | Middle Aged | 11 | 2025 | 33355 | 0.190 |
Why?
| | Aged | 8 | 2025 | 23798 | 0.190 |
Why?
| | Capsid Proteins | 1 | 2022 | 94 | 0.190 |
Why?
| | Otolaryngology | 1 | 2023 | 96 | 0.180 |
Why?
| | Fires | 1 | 2022 | 90 | 0.180 |
Why?
| | Trypanosoma | 1 | 2020 | 8 | 0.170 |
Why?
| | Spheniscidae | 1 | 2020 | 2 | 0.170 |
Why?
| | Hypersensitivity | 1 | 2023 | 256 | 0.160 |
Why?
| | Biological Products | 1 | 2023 | 219 | 0.160 |
Why?
| | Faculty, Medical | 1 | 2023 | 283 | 0.160 |
Why?
| | Humans | 22 | 2025 | 137514 | 0.160 |
Why?
| | Clinical Audit | 1 | 2019 | 13 | 0.160 |
Why?
| | Insect Vectors | 1 | 2019 | 37 | 0.160 |
Why?
| | Borrelia | 1 | 2019 | 8 | 0.150 |
Why?
| | Lizards | 1 | 2019 | 36 | 0.150 |
Why?
| | Classification | 1 | 2018 | 21 | 0.150 |
Why?
| | Leadership | 1 | 2023 | 382 | 0.150 |
Why?
| | Patient Care Management | 1 | 2018 | 56 | 0.150 |
Why?
| | Male | 13 | 2025 | 67718 | 0.150 |
Why?
| | Remote Sensing Technology | 1 | 2018 | 19 | 0.150 |
Why?
| | Female | 14 | 2025 | 73162 | 0.140 |
Why?
| | Transcriptome | 2 | 2021 | 974 | 0.140 |
Why?
| | Bacteria | 1 | 2025 | 858 | 0.140 |
Why?
| | Eye | 1 | 2019 | 108 | 0.140 |
Why?
| | Disease Progression | 3 | 2020 | 2755 | 0.140 |
Why?
| | Linear Models | 1 | 2020 | 851 | 0.140 |
Why?
| | Air Pollutants | 1 | 2022 | 428 | 0.140 |
Why?
| | Adult | 9 | 2025 | 37821 | 0.130 |
Why?
| | Microbiota | 1 | 2025 | 763 | 0.130 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 451 | 0.130 |
Why?
| | Decision Support Systems, Clinical | 1 | 2019 | 219 | 0.120 |
Why?
| | Glucocorticoids | 1 | 2019 | 599 | 0.120 |
Why?
| | Biomedical Research | 1 | 2019 | 689 | 0.100 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1770 | 0.090 |
Why?
| | Electronic Health Records | 1 | 2019 | 1040 | 0.090 |
Why?
| | Obesity | 2 | 2022 | 2974 | 0.080 |
Why?
| | Rats | 1 | 2019 | 5676 | 0.080 |
Why?
| | Antarctic Regions | 2 | 2020 | 25 | 0.080 |
Why?
| | Ecosystem | 2 | 2024 | 592 | 0.070 |
Why?
| | Comorbidity | 2 | 2022 | 1618 | 0.060 |
Why?
| | Endangered Species | 1 | 2025 | 16 | 0.060 |
Why?
| | Ear Neoplasms | 1 | 2025 | 9 | 0.060 |
Why?
| | Neurilemmoma | 1 | 2025 | 24 | 0.060 |
Why?
| | Ear, Inner | 1 | 2025 | 48 | 0.060 |
Why?
| | Lakes | 1 | 2024 | 26 | 0.050 |
Why?
| | Tanzania | 1 | 2024 | 58 | 0.050 |
Why?
| | Metagenome | 1 | 2024 | 147 | 0.050 |
Why?
| | Omalizumab | 1 | 2023 | 51 | 0.050 |
Why?
| | Cochlear Implants | 1 | 2024 | 110 | 0.050 |
Why?
| | Bronchodilator Agents | 1 | 2023 | 248 | 0.050 |
Why?
| | Gene Expression Regulation, Viral | 1 | 2021 | 93 | 0.040 |
Why?
| | Precision Medicine | 1 | 2025 | 426 | 0.040 |
Why?
| | Smoke | 1 | 2022 | 144 | 0.040 |
Why?
| | DNA, Protozoan | 1 | 2020 | 31 | 0.040 |
Why?
| | Ranidae | 1 | 2020 | 14 | 0.040 |
Why?
| | RNA, Ribosomal, 18S | 1 | 2020 | 25 | 0.040 |
Why?
| | Minority Groups | 1 | 2023 | 269 | 0.040 |
Why?
| | Vertebrates | 1 | 2020 | 59 | 0.040 |
Why?
| | Passeriformes | 1 | 2020 | 33 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2025 | 5772 | 0.040 |
Why?
| | Particulate Matter | 1 | 2022 | 314 | 0.040 |
Why?
| | Logistic Models | 1 | 2025 | 2064 | 0.040 |
Why?
| | Host-Parasite Interactions | 1 | 2020 | 106 | 0.040 |
Why?
| | International Cooperation | 1 | 2019 | 198 | 0.040 |
Why?
| | Australasia | 1 | 2018 | 2 | 0.040 |
Why?
| | Medication Therapy Management | 1 | 2019 | 75 | 0.040 |
Why?
| | Symptom Flare Up | 1 | 2018 | 40 | 0.040 |
Why?
| | Humpback Whale | 1 | 2018 | 2 | 0.040 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2021 | 538 | 0.040 |
Why?
| | Internationality | 1 | 2018 | 155 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2025 | 3546 | 0.030 |
Why?
| | Specialization | 1 | 2018 | 143 | 0.030 |
Why?
| | Environmental Exposure | 1 | 2022 | 575 | 0.030 |
Why?
| | Needs Assessment | 1 | 2019 | 368 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2025 | 3420 | 0.030 |
Why?
| | Delphi Technique | 1 | 2018 | 273 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2025 | 15628 | 0.030 |
Why?
| | Computational Biology | 1 | 2021 | 645 | 0.030 |
Why?
| | Biological Evolution | 1 | 2020 | 466 | 0.030 |
Why?
| | Seasons | 1 | 2018 | 546 | 0.030 |
Why?
| | Consensus | 1 | 2018 | 685 | 0.030 |
Why?
| | Disease Management | 1 | 2019 | 625 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2022 | 2857 | 0.030 |
Why?
| | Phenotype | 1 | 2022 | 3205 | 0.030 |
Why?
| | RNA | 1 | 2020 | 924 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2023 | 5427 | 0.020 |
Why?
| | Prevalence | 1 | 2018 | 2719 | 0.020 |
Why?
| | Risk Factors | 1 | 2018 | 10356 | 0.010 |
Why?
|
|
Harvey's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|